+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07488754

Study of Local Targeted Alpha Therapy Using 225AcAc-DOTA-SP After Standard Treatment in Adults with High-Grade Glioma WHO G3-G4

Led by Medical University of Warsaw · Updated on 2026-04-06

35

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Brain tumors make up a small but significant portion of all cancers and are responsible for a notable percentage of cancer-related deaths. Gliomas, especially high-grade types like WHO grade 3 and 4, are common and challenging to treat due to their aggressive and infiltrative nature. Current treatments include surgery, radiotherapy, and chemotherapy, but survival rates remain low, highlighting the need for new approaches such as targeted therapies using neuropeptides labeled with alpha emitters. This study evaluates the safety and effectiveness of a local targeted therapy using the alpha emitter 225AcAc-DOTA-SP in patients with newly diagnosed high-grade gliomas after standard treatment. Participants will receive up to six cycles of this therapy administered directly to the tumor or resection cavity via a catheter placed during surgery. The treatment involves careful preparation, imaging, and monitoring, with hospitalization typically lasting about three days per cycle. Follow-up includes regular MRI scans and clinical assessments to track disease progression and side effects. Participants will undergo extensive evaluations including neurological exams, blood and urine tests, and imaging studies before, during, and after treatment. Researchers will measure progression-free survival and overall survival as primary outcomes, while closely monitoring safety and any adverse events. The study lasts approximately three years, with ongoing follow-up for patients who remain alive. Biological samples collected during surgery will be analyzed for genetic and pathological information, and all patient data will be anonymized to protect privacy.

CONDITIONS

Brief Title

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

Research Team

P

Przemysław Kunert, Professor MD PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here